NCT03923036

Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer

Anticancer Drug-induced Cardiac Adverse Events in Metastatic Colorectal Cancer: Insights From the French County Calvados Registry

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,000 (estimated)
• Sponsor: University Hospital, Caen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a retrospective observational study that evaluates the rate of cardiovascular adverse events leading to hospitalization in metastatic colorectal cancer in the French county Calvados by drug exposure.

Detailed description

This study investigates the characteristics of cardiovascular adverse events leading to hospitalization in metastatic colorectal cancer. Descriptive analysis will include incidence, type of cardiovascular adverse events. We will explore the incidence of cardiovascular adverse events with regard of the antineoplastic drug exposures. This will provide information about the individual drug safety profiles.

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Antineoplastic Agents	Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.

Timeline

• Start date: 2019-04-01
• Primary completion: 2019-06-01
• Completion: 2019-06-01
• First posted: 2019-04-22
• Last updated: 2019-04-22

Locations

1 site across 1 country: France